Cerebrolysin sodium capsules combined with ticlopidine in treatment of patients with acute cerebral infarction beyond thrombolytic time window
Objective To explore the efficacy of cerebrolysin sodium capsules combined with ticlopidine for patients with acute cerebral infarction beyond the thrombolytic time window.Methods Eighty-one patients with acute ischemic stroke beyond the thrombolytic time window treated at Tongchuan People's Hospital from April 2019 to August 2023 were selected and divided into an observation group(41 patients)and a control group(40 patients)by the random number table method.There were 17 males and 24 females in the observation group;they were(52.23±9.06)years old;their disease course was(37.65±18.77)h;16 cases had infarction on basal ganglia,13 cases cerebellum,and 12 cases brainstem;they were treated with citicoline sodium capsules,1-2 capsules per time,3 times/d,for 14 d,and dripped tirofiban at 0.4 μg/(kg·min)in the first 30 min and at 0.1 μg/(kg·min)after 30 min for 48 h.There were 21 males and 19 females in the control group;they were(50.68±9.76)years old;their disease course was(38.46±19.20)h;14 cases had infarction on basal ganglia,12 cases cerebellum,and 14 cases brainstem;they were treated with tirofiban.The efficacies,cerebral blood flow indicators[peak flow velocity(Vp),mean flow velocity(Vm),and pulsatility index(PI)],platelet parameters[platelet crit(PCT),platelet count(PLT),and mean platelet volume(MPV)],neurological function[evaluated by the National Institutes of Health Stroke Scale(NIHSS)],and daily living ability[evaluated by the Functional Independence Measure(FIM)scale]were compared between the two groups before and after 14 days'treatment.t and x2 tests were used.Results After 14 days'treatment,the effective treatment rate in the observation group was higher than that in the control group[97.56％(40/41)vs.82.50％(33/40)],with a statistical difference between the two groups(x2=4.042,P＜0.05).The observation group had higher Vp and Vm and lower PI than the control group[(73.11±8.22)cm/s vs.(64.35±7.19)cm/s,(35.08±3.53)cm/s vs.(32.35±2.97)cm/s,and(0.71±0.12)vs.(0.88±0.13);t=5.100,3.762,and 6.118;all P＜0.05].The PCT and PLT were higher and the MPV was lower in the observation group than in the control group[(0.35±0.08)％vs.(0.29±0.06)％,(255.08±38.53)x109·L1 vs.(225.35±35.97)x109.L1,and(8.71±0.92)fl vs.(10.88±1.03)fl;t=3.811,3.588,and 10.006;all P＜0.05].The NIHSS score was lower and the FIM score was higher in the observation group than in the control group[(3.58±1.17)vs.(4.36±1.21)and(108.11±15.80)vs.(93.58±13.33);t=2.950 and 4.468;both P＜0.05].Conclusion Cerebrolysin sodium capsules combined with ticlopidine for patients with acute cerebral infarction can improve their cerebral blood flow and platelet parameters,alleviate their neurological deficit symptoms,and enhance their daily living abilities.
Acute cerebral infarctionBeyond thrombolysis time windowCerebrolysin sodium capsulesTiclopidineNeurological function
万方数据
维普
